Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug

20 Jul 2026 MHRA touts uptick in approvals in 2025-2026 annual report The UK's Medicines and Healthcare products Regulatory Agency (MHRA) touted its achievements over the last year its 2025-2026 annual report to Parliament, which includes approving more new drugs than the prior year, removing a record number of illegal drugs from circulation, and taking steps to advance the regulation of artificial intelligence (AI) in healthcare. Regulatory News